
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

APRIL 5, 2005
Date of Report (Date of earliest event reported)

ORAGENICS, INC.
(Exact name of registrant as specified in its charter)

FLORIDA	000-50614	59-3410522
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

12085 RESEARCH DRIVE
ALACHUA, FLORIDA 32615
(Address of principal executive offices including zip code)

(386) 418-4018
Registrant's telephone number, including area code

NONE

(Former name or former address, if changed since last report.)

ITEM 8.01 OTHER EVENTS

Oragenics, Inc. issued a press release to announce that it has developed a proprietary manufacturing process for its novel antibiotic drug candidate, Mutacin 1104, to allow the Company to manufacture sufficient quantities to enable them to begin preclinical studies.

ITEM 9.01 FINANCIAL INFORMATION AND EXHIBITS

EXHIBIT NO.	DESCRIPTION
-----	-----
99.1	Press Release

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 5th day of April, 2005.

ORAGENICS, INC.
(REGISTRANT)

BY: /s/ Mento A. Soponis

Mento A. Soponis
President and Chief Executive Officer

Contact:

For Media:

Chuck Soponis
Chief Executive Officer
Oragenics, Inc.
(386) 418-4018

Joan Kureczka
Kureczka/Martin Associates
(415) 821-2413
Jkureczka@comcast.net

FOR IMMEDIATE RELEASE

ORAGENICS ANNOUNCES SUCCESSFUL MANUFACTURING
OF NOVEL ANTIBIOTIC

Company Advances Mutacin 1140 into Preclinical Development

ALACHUA, FL (April 4, 2005): Oragenics, Inc. (AMEX:ONI) today announced that the company has developed a proprietary manufacturing process for its novel antibiotic drug candidate, Mutacin 1140, which overcomes a previous hurdle to that molecule's development. The company said that it can now manufacture Mutacin 1140 in sufficient quantities to enable Oragenics to conduct preclinical studies needed to enable the filing of an Investigational New Drug (IND) application for that compound. Mutacin 1140 is a novel peptide antibiotic.

Chuck Soponis, Oragenics chief executive officer commented, "Previously this peptide has been difficult to produce in sufficient quantities to permit its preclinical and clinical development --either synthetically, because of its complex chemical structure or through standard fermentation methods. Now we have solved this production challenge and can move forward with the necessary preclinical studies over the next 15 to 18 months to support the filing of an IND for Mutacin 1140."

About Oragenics

Oragenics, Inc. is an early stage biotechnology company focused on the development and licensure of innovative products and technologies for improving human health. The company's lead product is a novel oral rinse for the prevention of tooth decay, which is anticipated to enter clinical trials in 2005. The company is also developing a novel antibiotic with broad-spectrum activity against gram-positive bacteria and a probiotic product aimed at maintaining oral health. The company is headquartered in Alachua, Florida. For more information about Oragenics, please consult the company's website at www.oragenics.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements which reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe", "expect", "anticipate", "intend", "estimate", "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are

subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to (1) the ability to successfully complete development and commercialization of Oragenics' Replacement Therapy for prevention of tooth decay, novel antibiotic, and probiotic product for oral health; (2) the ability to produce Mutacin 1140 in commercial quantities; (3) the ability to obtain substantial additional funding; (4) the ability to develop and commercialize products before our competitors do; (5) the ability to develop commercial products with the in-licensed technology; and (6) other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

###